Market view
Stock chart
Coverage
Analyses on Lineage Therap (2)
- May 13, 2026May 13, 2026
- Follow-up
Lineage follow-up: how much of the Roche economics really reaches shareholders
The Roche agreement still gives Lineage a meaningful OpRegen option, but the first milestone shows that headline milestones are not the same as accessible shareholder value.
Lineage Cell Therapeutics in the first quarter: science advanced, cash still sets the pace
Lineage shows real scientific progress across several programs, but the first quarter of 2026 emphasizes that the company is still buying time until an external milestone turns the platform into accessible cash.
Same sector
